DNA vs PRME: stock comparison and AI forecast
Ginkgo Bioworks Holdings, Inc. (DNA) and Prime Medicine, Inc. (PRME) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DNA Ginkgo Bioworks Holdings, Inc.
- Market Cap
- $725M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
PRME Prime Medicine, Inc.
- Market Cap
- $825M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- PRME is 1.1 times larger than DNA by market capitalization ($825M against $725M).
- DNA turns -260.0% of its revenue into net income, against -4678.6% for PRME.
- PRME carries 5.26 times debt per unit of equity, against 1.36 times for DNA.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DNA | PRME |
|---|---|---|
| Market Cap | $725M | $825M |
| P/B Ratio | 1.72x | 20.73x |
| EPS | $-5.64 | $-1.18 |
| Book Value/Share | $6.24 | $0.22 |
| Revenue/Share | $1.66 | – |
| FCF/Share | $-2.60 | $-0.86 |
Profitability & Margins
| Metric | DNA | PRME |
|---|---|---|
| ROE | -69.2% | -472.0% |
| ROA | -29.4% | -75.5% |
| ROIC | -31.7% | -90.4% |
| Operating Margin | -259.9% | -4893.4% |
| Net Margin | -260.0% | -4678.6% |
| EBT Margin | -264.1% | -4893.4% |
| Tax Rate | 0.2% | 0.0% |
Financial Health
| Metric | DNA | PRME |
|---|---|---|
| Current Ratio | 4.57x | 3.05x |
| D/E Ratio | 1.36x | 5.26x |
| Financial Leverage | 2.36x | 6.26x |
| Interest Coverage | -18.1x | – |
| Working Capital | $260M | $65M |
Cash Flow
| Metric | DNA | PRME |
|---|---|---|
| Operating Cash Flow | -$170M | -$156M |
| Free Cash Flow | -$175M | -$157M |
| Capital Spending | -$5M | -$800K |
| FCF/Sales | -156.3% | – |
| CapEx/Sales | 4.1% | – |
Operational Efficiency
| Metric | DNA | PRME |
|---|---|---|
| Asset Turnover | 0.11x | – |
| Receivables Turnover | 8.6x | – |
| Fixed Assets Turnover | 0.7x | – |
| Days Sales Outstanding | 42 days | – |
Income Statement
| Metric | DNA | PRME |
|---|---|---|
| Total Revenue | $112M | – |
| Operating Income | -$291M | -$197M |
| Net Income | -$291M | -$188M |
| R&D Expense | $216M | $146M |
Dividend & Shareholder Information
| Metric | DNA | PRME |
|---|---|---|
| Shares Outstanding | 67M | 181M |
DNA vs PRME: stock comparison and AI forecast
Which is bigger, DNA or PRME?
PRME is 1.1 times larger than DNA by market capitalization ($825M against $725M).
Which one does Intratio's AI model rank higher, DNA or PRME?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.